AIM IMMUNOTECH INC (AIM) Stock News

USA - NYSEARCA:AIM - US00901B1052 - Common Stock

2.6 USD

0 (0%)

Last: 9/12/2025, 8:04:00 PM

2.6001 USD

0 (0%)

After Hours: 9/12/2025, 8:04:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AIM Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

25 days ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

a month ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

a month ago - By: Zacks Investment Research - Mentions: FGEN

FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

a month ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

6 months ago - By: Benzinga

Earnings Preview For AIM ImmunoTech

a month ago - By: Benzinga - Mentions: BTCM DE TIC DFLI ...

Earnings Scheduled For August 14, 2025

a month ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

2 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

2 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering

2 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

2 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

3 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements

3 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Resumes Trading on NYSE American

3 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

3 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

3 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

4 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

5 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

5 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

6 months ago - By: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update